ASTH vs OFIX: fair value comparison
Astrana Health, Inc. and Orthofix Medical Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ASTH currently sits closer to the top of our discount ranking.
| ASTH | OFIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $38.60 | $9.43 |
| 12-month range | $22.32–$49.81 | $9.27–$16.06 |
| Sector rank | #8 of 113 Healthcare | #13 of 113 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: ASTH fair value analysis · OFIX fair value analysis